Novo Nordisk sells hit weight-loss drug in China

Novo Nordisk Launches Wegovy Weight-Loss Drug in China
Novo Nordisk has launched its blockbuster Wegovy weight-loss drug in China, adding the world’s second-largest economy to its growing list of markets where appetite for the drugs are rising.The first prescription for Wegovy in China will be issued at a public hospital in Shanghai this week and will cost about 1,
Novo Nordisk's obesity drug Wegovy goes on sale in China
Novo Nordisk's blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday, as the Asian nation battles high rates of obesity.A Novo Nordisk spokesperson confirmed to AFP on Tuesday that the drug was "now available in China" for the treatment of adults with obesity and those overweight with at least one weight-related comorbidity.
Novo Nordisk sells hit weight-loss drug in China—at fraction of US price
Patients in China will be able to purchase the blockbuster weight-loss drug Wegovy for 1,400 yuan, or about $193, just a fraction of the US list price of $1,349, according to media reports.
Novo’s Wegovy Launched in China at a Fraction of US Price
Wegovy is being made available to Chinese patients five months after its approval in the country. Novo will sell the medicine for about $193.27 for a one-month supply.
Weight loss drug makers want more insurance plans to cover Wegovy and Zepbound
Weight-loss drug makers are directly targeting employers in a campaign to expand health insurance coverage of their popular, but pricey, medications.
Novo Nordisk launches obesity drug Wegovy in China
Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.
Medicaid dominates coverage of Novo, Lilly weight-loss drugs
State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access to Novo Nordisk's Wegovy or Eli Lilly's Zepbound.
Makers of Weight-Loss Drugs Want Your Employer to Pay for Them
Lilly’s reps presented a slide deck that laid out data on the effectiveness of Lilly’s weight-loss drug Zepbound. The goal of the hourlong meeting with association leaders was to cement one core message: Obesity care is healthcare.
Weight-loss drug coverage rises among largest US employers, Mercer survey finds
About 44% of U.S. employers with 500 or more employees cover drugs for weight loss in 2024, up from 41% in 2023, according to a survey from consulting firm Mercer released on Wednesday. Mercer also said 64% of U.
Eli Lilly, Novo Nordisk urge employers to cover cost of weight loss drugs
Drugmakers are likewise reaching out to other employers with the message that treating obesity will ultimately save them money. Eli Lilly's Zepbound and Novo Nordisk's Wegovy, both priced at over $1,000 a month,
Weight-Loss Drugmakers Press Companies To Cover Cost Of Treatment
The efforts by Eli Lilly and Novo Nordisk could be a game-changer for sales, which some analysts say could exceed $100 billion a year.
Is Novo Nordisk Stock a Buy Right Now?
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
Daily9h
Novo Nordisk Enters China's Obesity Market with Wegovy Launch, Eyes 180 Million Patients
The move intensifies the competition with Eli Lilly, which secured approval for its weight loss drug in China in July but has ...
Benzinga.com2d
Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost
Novo Nordisk's Wegovy launch in China begins in Shanghai at $194 per four-injection pack, significantly cheaper than ...
24/7 Wall St1d
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
A Scandinavian economic behemoth, Novo Nordisk is the highest valued company in Europe at over $500 billion, which ...
The Financial Times3d
Novo Nordisk readies trial results for next-generation weight-loss drug
That compares with up to 16 per cent from Novo Nordisk’s Wegovy, and up to 22.5 per cent from Eli Lilly’s rival Mounjaro when administered alongside lifestyle interventions such as improved ...
Novo Nordisk’s Blockbuster Wegovy Drug Sales Beat Expectations
The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.
STAT1d
Pharmalittle: We’re reading about a key Merck drug trial, cheap Wegovy in China, and more
Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 billion deal
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...